Novacyt reaches the first close of its financing to support the acquisition of Primerdesign and provides positive business update

Paris, France and Cambridge, UK – 1st April 2016, – Novacyt (ALTERNEXT: ALNOV), an international specialist in cancer and infectious disease diagnostics, updates the market on its intended acquisition of Primerdesign Ltd (“Primerdesign”) and confirms that it has reached first close in the earlier disclosed €7.0m financing. Novacyt Primerdesign Acquisition Update PR (1-4-16)

Visit Page

Novacyt shareholders approve the acquisition of Primerdesign

Novacyt (ALTERNEXT: ALNOV), an international specialist in cancer and infectious disease diagnostics, held Monday 22 February an Extraordinary General Meeting (“EGM”) related to the acquisition of Primerdesign Ltd (“Primerdesign”) and the financing of this acquisition. All resolutions were duly passed by the shareholders. Download press release

Visit Page

Novacyt expands distribution presence in Asia Pacific

Novacyt (ALTERNEXT: ALNOV), an international specialist in cancer and infectious disease diagnostics, today announces that it has appointed MDL Asia Pty Ltd (“MDL” or “MDL Asia”) as its marketing and distribution partner in the Asia Pacific region, excluding Greater China. Download press release

Visit Page